Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 1/20 | 0.52 |
| ▸ | PTPRC | P08575 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587576 | 0.92 | CCKBR (0.51) | CCKBR | |
| SCHEMBL2247862 | 0.87 | CCKBR (0.51) | CCKBRPTPRCCTSLPTPN13 | |
| SCHEMBL3589250 | 0.86 | PTPRC (0.52) | CCKBRPTPRCCTSLPTPN13 | |
| SCHEMBL2246128 | 0.85 | CCKBR (0.50) | CCKBRL3MBTL1 | |
| SCHEMBL2245265 | 0.83 | L3MBTL1 (0.72) | CCKBRL3MBTL1 | |
| SCHEMBL2249422 | 0.82 | HPGDS (0.59) | PTPRCCTSLPTPN13 | |
| SCHEMBL2247265 | 0.80 | MMP2 (0.63) | PTPRCCTSLPTPN13 | |
| SCHEMBL2247972 | 0.78 | CCKBR (0.49) | CCKBR | |
| SCHEMBL4622305 | 0.77 | CCKBR (0.50) | CCKBRPTPRCCTSLPTPN13 | |
| SCHEMBL2250363 | 0.77 | L3MBTL1 (0.62) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | CCKBR 2177/4885PTPRC 2656/4885CTSL 294/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | CCKBR 2177/4885PTPRC 2656/4885CTSL 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.